MBX 1416 (INN imapextide)
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postbariatric Hypoglycemia
Conditions
Postbariatric Hypoglycemia
Trial Timeline
Aug 26, 2025 → Jan 26, 2026
NCT ID
NCT07029412About MBX 1416 (INN imapextide)
MBX 1416 (INN imapextide) is a phase 2 stage product being developed by MBX Biosciences for Postbariatric Hypoglycemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07029412. Target conditions include Postbariatric Hypoglycemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07029412 | Phase 2 | Recruiting |
Competing Products
1 competing product in Postbariatric Hypoglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C) | MBX Biosciences | Phase 1 | 28 |
Other Products from MBX Biosciences
MBX 2109Phase 2
47
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injectionPhase 2
47
MBX 4291 + PlaceboPhase 1
28
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)Phase 1
28
MBX 2109 (Part A) + MBX 2109 (Part B) + PlaceboPhase 1
28